After finishing at $94.02 in the prior trading day, Moderna Inc (NASDAQ: MRNA) closed at $96.20, up 2.32%. In other words, the price has increased by $+2.18 from its previous closing price. On the day, 3083183 shares were traded. MRNA stock price reached its highest trading level at $97.47 during the session, while it also had its lowest trading level at $92.58.
Ratios:
Our goal is to gain a better understanding of MRNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 22 when Hoge Stephen sold 15,000 shares for $100.00 per share. The transaction valued at 1,500,000 led to the insider holds 1,513,433 shares of the business.
Bancel Stephane sold 26,351 shares of MRNA for $2,342,098 on Feb 16. The Chief Executive Officer now owns 5,460,224 shares after completing the transaction at $88.88 per share. On Feb 16, another insider, Hoge Stephen, who serves as the President of the company, sold 10,542 shares for $88.88 each. As a result, the insider received 936,981 and left with 1,528,433 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 36.76B and an Enterprise Value of 29.40B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.35 while its Price-to-Book (P/B) ratio in mrq is 2.65. Its current Enterprise Value per Revenue stands at 4.35 whereas that against EBITDA is -8.96.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $163.24, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is 97.52, while the 200-Day Moving Average is calculated to be 103.26.
Shares Statistics:
The stock has traded on average 4.95M shares per day over the past 3-months and 4.76M shares per day over the last 10 days, according to various share statistics. A total of 382.00M shares are outstanding, with a floating share count of 334.65M. Insiders hold about 12.23% of the company’s shares, while institutions hold 66.12% stake in the company. Shares short for MRNA as of Jan 31, 2024 were 20.88M with a Short Ratio of 4.22, compared to 24.19M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.48% and a Short% of Float of 7.29%.
Earnings Estimates
Its stock is currently analyzed by 13 different market analysts. On average, analysts expect EPS of -$3.16 for the current quarter, with a high estimate of -$1.94 and a low estimate of -$4.11, while EPS last year was $0.19. The consensus estimate for the next quarter is -$3.27, with high estimates of -$2.04 and low estimates of -$3.94.
Analysts are recommending an EPS of between -$5.32 and -$8.29 for the fiscal current year, implying an average EPS of -$6.97. EPS for the following year is -$4.92, with 21 analysts recommending between -$1.01 and -$7.6.
Revenue Estimates
A total of 24 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $6.63B, while the lowest revenue estimate was $3.69B, resulting in an average revenue estimate of $4.38B. In the same quarter a year ago, actual revenue was $6.85B, down -36.10% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $5.02B in the next fiscal year. The high estimate is $8.01B and the low estimate is $3.23B. The average revenue growth estimate for next year is up 14.60% from the average revenue estimate for this year.
